Transcranial Direct Current Stimulation for Cognitive Deficits in Multiple Sclerosis

This study is investigating if low-level electrical stimulation, called transcranial Direct Current Stimulation (tDCS), can improve verbal memory in people with relapsing-remitting multiple sclerosis (RRMS) who have memory problems. You would receive either active tDCS or a sham (inactive) tDCS. Researchers will compare changes in your verbal memory and other thinking abilities after treatment. To join, you must be 18-65 years old, have RRMS, a memory retrieval deficit, and be fluent in English. The study aims to enroll 100 participants, but its current status is unclear.

Study design
This study is interventional and will randomly assign participants to either active transcranial Direct Current Stimulation (tDCS) or sham tDCS. It plans to enroll 100 participants.
What's involved
You would receive 10 sessions of either active or sham tDCS, each lasting 20 minutes. You will also have neuropsychological and EEG assessments at baseline, immediately after treatment, and two months later.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for two months after completing treatment to assess changes in verbal retrieval and other cognitive abilities.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05958381

Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation

Recruiting
NAAges 18–65InterventionalTreatment
The University of Texas at Dallas
~100 participants
Updated 2026-08-14 on ClinicalTrials.gov
What's tested:Transcranial Direct Current StimulationSham transcranial direct current stimulation

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Treatment group differences in change from Baseline to 1-week Post-Treatment on Category Fluency
Measured over Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment
+3 more outcomes measured
Multiple Sclerosis, Relapsing-Remitting
1 sites across 1 states
Texas1
  • John Hart, Jr, MD · PRINCIPAL_INVESTIGATOR · The University of Texas at Dallas

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

dementia of any type
epilepsy or other seizure disorders
severe traumatic brain injury
brain tumor
present drug abuse
stroke
blood vessel abnormalities in the brain
Parkinson's disease
Huntington's disease
anti-convulsants
L-dopa
carbamazepine
sulpiride
pergolide
lorazepam
rivastigmine
dextromethorphan
D-cycloserine
flunarizine
ropinirole
stimulants (dextroamphetamine/amphetamine/modafinil/armodafinil) must be stopped during enrollment
  • Treatment group differences in change from Baseline to 1-week Post-Treatment on Category FluencyOutcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment

    Evaluation of treatment group differences in change on Category Fluency from baseline to 1-week post-treatment. Metric: Number of Correct Items Generated

  • Treatment group differences in change from Baseline to 2-months Post-Treatment on Category FluencyOutcome measures will be assessed as change over a period of 13 weeks: Change from baseline to 2-month Post-Treatment

    Evaluation of treatment group differences in change on Category Fluency from baseline to 2-months post-treatment. Metric: Number of Correct Items Generated

  • Treatment group differences in change from Baseline to 1-week Post-Treatment on COWATOutcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment

    Evaluation of treatment group differences in change on COWAT from baseline to 1-week post-treatment. Metric: Number of Correct Items Generated

  • Treatment group differences in change from Baseline to 2-months Post-Treatment on COWATOutcome measures will be assessed as change over a period of 13 weeks: Change from baseline to 2-months Post-Treatment

    Evaluation of treatment group differences in change on COWAT from baseline to 2-months post-treatment. Metric: Number of Correct Items Generated